Inflammatory demyelinating polyneuropathy versus leptomeningeal disease following Ipilimumab

Inflammatory demyelinating polyneuropathy versus leptomeningeal disease following Ipilimumab

Abstract Background Ipilimumab is an FDA-approved anti-CTLA-4 monoclonal antibody used in treatment of metastatic melanoma. We present an unusual neurological complication of Ipilimumab therapy and the diagnostic dilemma it caused. Case presentation A 42 year old male with Stage IV metastatic melano...

Full description

Bibliographic Details
Main Authors: Lorraine Cafuir, David Lawson, Nilesh Desai, Vita Kesner, Alfredo Voloschin
Format: Article
Language:English
Published: BMJ Publishing Group 2018-01-01
Series:Journal for ImmunoTherapy of Cancer
Subjects:
Ipilimumab
Melanoma
Leptomeningeal carcinomatosis
Inflammatory demyelinating polyneuropathy
Autoimmune
Immunotherapy
Online Access:http://link.springer.com/article/10.1186/s40425-018-0318-x

Internet

http://link.springer.com/article/10.1186/s40425-018-0318-x

Similar Items